Previous Close | 27.40 |
Open | 26.60 |
Bid | 26.20 x N/A |
Ask | 26.40 x N/A |
Day's Range | 26.60 - 26.60 |
52 Week Range | 21.40 - 32.80 |
Volume | |
Avg. Volume | 0 |
Market Cap | 1.462B |
Beta (5Y Monthly) | 1.01 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.27 |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 35.00 |
Despite Challenges, Company Shows Promising Growth in Key Areas
Supernus Pharmaceuticals ( NASDAQ:SUPN ) First Quarter 2024 Results Key Financial Results Revenue: US$143.6m (down 6.6...
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. A live webcast with presentation slides will